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Abstract
Purpose There are no comprehensive guidelines for the use of FDG PET in the following three clinical scenarios: (1) diagnostic
work-up of patients with idiopathic Parkinson’s disease (PD) at risk of future cognitive decline, (2) discriminating idiopathic PD
from progressive supranuclear palsy, and (3) identifying the underlying neuropathology in corticobasal syndrome.
Methods We therefore performed three literature searches and evaluated the selected studies for quality of design, risk of bias,
inconsistency, imprecision, indirectness and effect size. Critical outcomes were the sensitivity, specificity, accuracy, positive/
negative predictive value, area under the receiving operating characteristic curve, and positive/negative likelihood ratio of FDG
PET in detecting the target condition. Using the Delphi method, a panel of seven experts voted for or against the use of FDG PET
based on published evidence and expert opinion.
Results Of 91 studies selected from the three literature searches, only four included an adequate quantitative assessment of the
performance of FDG PET. The majority of studies lacked robust methodology due to lack of critical outcomes, inadequate gold
standard and no head-to-head comparison with an appropriate reference standard. The panel recommended the use of FDG PET
for all three clinical scenarios based on nonquantitative evidence of clinical utility.
Conclusion Despite widespread use of FDGPET in clinical practice and extensive research, there is still very limited good quality
evidence for the use of FDG PET. However, in the opinion of the majority of the panellists, FDG PET is a clinically useful
imaging biomarker for idiopathic PD and atypical parkinsonism associated with dementia.
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Introduction
There are no clear diagnostic guidelines on the role of FDG
PET in the diagnostic work-up of cognitive disorders and
dementia. Therefore, the European Association of Nuclear
Medicine (EANM) and the European Academy of
Neurology (EAN) came together in a joint initiative to provide
guidance to clinicians on the use of FDG PET in the context of
neurodegenerative diseases. The initiative included a set of 21
clinical scenarios, captured as PICO (Population, Intervention,
Comparison, Outcome) questions, that were addressed based
on literature evidence and expert consensus [1].
In this article, we focus on the assessment of the quality of
studies investigating the clinical utility of FDG PET for iden-
tifying patients with Parkinson’s disease (PD) who are at risk
of cognitive decline, and the utility of FDG PET in facilitating
the differential diagnosis of common forms of parkinsonism,
i.e. idiopathic PD, including the prodromal stage, progressive
supranuclear palsy (PSP) syndromes, and corticobasal syn-
drome (CBS). Multiple system atrophy (MSA), another neu-
rodegenerative disorder presenting with parkinsonismwas not
included in this review. MSA very seldom, if ever, affects
cognition and therefore it did not fall within our prespecified
condition restricting this review to studies on the role of FDG-
PET in Bthe diagnostic work-up of cognitive disorders and
dementia^.
Parkinson’s disease
PD is a common degenerative disorder. It is associated with an
increased incidence of cognitive impairment and dementia.
The pathology underlying this cognitive decline is variable:
while in some patients it is purely Lewy body pathology, in
many it is due to mixtures of amyloid, tau and Lewy body
pathology [2]. Any therapeutic intervention to stop cognitive
decline is likely to be most effective in the early stages of PD
or even during prodromal stages of PD. Consequently, it may
become important to identify patients at high risk of cognitive
decline before its onset. Older age, scores from nonmotor
assessments, reduced dopamine transporter uptake in the cau-
date, deficit on smell testing, CSF amyloid β (Aβ42) to t-tau
ratio, and APOE ε4 status are all known risk factors for cog-
nitive decline in patients with newly diagnosed PD [3]. Here
we report on the role of FDG PET in predicting cognitive
decline in PD.
Not all patients presenting with parkinsonism have idio-
pathic PD. There are alternative pathologies that can present
with parkinsonism and cognitive decline. Both PSP and CBS
can mimic PD in early stages and are particularly difficult to
diagnose in prodromal stages.
Progressive supranuclear palsy
The underlying neuropathology of PSP is a characteristic four-
repeat tau neuropathology [4]. There are a number of clinical
phenotypes of PSP which consist of different combinations of
motor, gait, language, cognitive and behavioural features [5].
The two most common phenotypes are PSP Richardson’s syn-
drome (PSP-RS) and the clinical phenotype that most closely
mimics idiopathic PD, PSP-parkinsonism (PSP-P) which of-
ten presents with asymmetrical tremor, bradykinesia and rigid-
ity. An initial positive response to levodopa treatment can be
misleading. Frequently only later in the disease course, when
patients develop additional features of impaired ocular move-
ments with vertical supranuclear gaze palsy, is a retrospective
diagnosis of PSP-P made.
Corticobasal syndrome
CBS is an atypical parkinsonian syndrome which consists of
dystonia, rigidity, akinesia, myoclonus, tremor and poor re-
sponse to levodopa. Typically, there is quite marked asymme-
try, including limb apraxia and the alien limb phenomenon.
Other features include speech and language impairment and
cognitive decline. The term CBS describes a clinical pheno-
type which has been shown to have a heterogeneous underly-
ing pathology. Corticobasal pathology is found only in about
50% of all clinically diagnosed patients. This has led to the
distinction between the clinical syndrome (CBS) and the path-
ological diagnosis (corticobasal degeneration, CBD). The oth-
er pathologies found at autopsy include Alzheimer’s disease
(AD), PSP and other tauopathies, dementia with Lewy bodies
and Creutzfeldt-Jakob disease. Based on this background,
three literature searches were performed to assess the quality
of evidence supporting the use of FDG PET in facilitating the
diagnosis of PD and atypical parkinsonism associated with
dementia where the underlying pathology is PSP or CBD.
Methods
Seven panellists, four from the EANM and three from the
EAN, were appointed to produce recommendations, taking
into consideration the incremental value of FDG PET as an
add-on investigation to a comprehensive clinical/
neuropsychological assessment, in facilitating the diagnosis
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and management of patients with parkinsonism. Consensus
recommendations were reached through a Delphi procedure
which was based on the expertise of the panellists. The
panellists were provided with comprehensive data regarding
the availability and quality of evidence, which was assessed
by an independent methodology team, as described by
Boccardi et al. [6]. Briefly, we searched the literature using
harmonized PICO (Population, Intervention, Comparison,
Outcome) questions. Thematic keywords were generated by
experts, and studies were selected based on eligibility criteria
described elsewhere [6]. Relevant data were extracted from
selected studies and assessed for quality of methodology, ac-
cording to European Federation of Neurological Societies
guidance [7] and for their relevance to FDG PET studies [6].
PICO questions for this review
In this review, the PICO questions asked whether Bperforming
FDG PET would add diagnostic value (in terms of increased
accuracy compared with neuropathological diagnosis,
biomarker-based diagnosis or diagnosis at follow-up) to stan-
dard clinical/neuropsychological assessment alone^, to:
& Identify brain dysfunction related to cognitive deteriora-
tion in patients with PD and cognitive impairment (PICO
question 12)
& Discriminate PSP from PD (PICO question 13)
& Identify the underlying pathological process in patients
with CBS (PICO question 15).
Eligibility criteria
Only original full papers published in English in international
journals with an impact factor were considered. Reviews,
management guidelines, abstracts and ‘grey’ literature were
excluded. Any sample size was permissible if pathology was
the gold standard for diagnosis. Otherwise, the minimum sam-
ple size was five for PSP and CBS, and 20 for PD.
Literature search
Electronic searches were performed using a harmonized key-
words string based on the specific PICO question, and includ-
ed a selection of terms chosen for being largely inclusive to
identify a broad range of papers. The strings contained a com-
mon part for FDG PET and a PICO question-specific part [6].
The MEDLINE, Embase and Google Scholar databases were
searched for studies published up to November 2015. The first
screening of all included studies was performed by the
panellist responsible for that PICO question (an expert neurol-
ogist, psychiatrist or nuclear physician) who could include
additional studies based on personal knowledge or forward
tracking from the references of papers. The full text of these
potentially eligible studies was then independently assessed
for eligibility by the methodology team.
Data extraction and quality assessment
To assess the evidence, data on study features, population of
interest, index test, gold/reference standard, and critical/proxy
outcomes were extracted (for more details see, Boccardi et al.
[6]). Data assessors for this review were D.A. for PICO ques-
tion 12, and F.G. and S.O. for PICO questions 13 and 15.
Critical outcomes were the validated measures of test perfor-
mance accuracy, sensitivity, specificity, AUC, positive and
negative predictive values (PPV, NPV) and likelihood ratios
(LR). Additional proxy outcomes for PICO questions 13 and
15 were accuracy of differential diagnosis between typical and
atypical parkinsonism. The prediction of years of survival was
an additional outcome specific to PICO question 15.
The quality of evidence was consensually assessed by the
methodology team based on the study design, gold/reference
standard, FDG PET image assessment method (visual or semi-
quantitative), risk of bias, index test imprecision, applicability,
effect size, and effect inconsistency. A final assessment of the
relative availability of evidence was formulated, taking into
account evidence available from all 21 PICO questions. This
ranking was summarized as ‘very poor/lacking’, ‘poor’, ‘fair’
or ‘good’. For further details about data extraction and quality
assessment see Boccardi et al. [6].
Results
Among the three PICO questions included in this review, only
four of the 91 studies examined included the critical outcomes
needed for the three questions of interest (Fig. 1). Our data
extraction and assessment failed to find definitive evidence for
the clinical utility of FDG PET for identifying neurodegener-
ation associated with cognitive decline in PD and for discrim-
inating PSP from PD. However, we ranked the evidence
supporting the clinical use of FDG PET for discriminating
between different underlying pathologies in patients with
CBS as Bfair^ (see Table 1, and Nobili et al. [1]).
PICO question 12: Identify PD-related
neurodegeneration associated with impaired
cognition
Of the 111 studies identified and screened by the leading
panellist (Z.W.), 21 were sent to the methodology team for data
extraction and assessment (see Fig. 1). Eleven studies were
excluded for the following reasons: seven [11–17] provided
no critical outcomes or did not have the minimum sample size,
two [18, 19] did not include the target population (i.e. PD
1536 Eur J Nucl Med Mol Imaging (2018) 45:1534–1545
Fig. 1 PRISMA flow chart of selected studies to identify brain dysfunction related to cognitive deterioration (PICO question 12), to discriminate PSP from
PD (PICO question 13), and to identify the underlying pathological process in patients with CBS (PICO question 15) [8]
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patients without cognitive impairment), in one [20] the index
investigation was proton magnetic resonance spectroscopy, and
one [21] focused on cognitive impairment and cerebral
hypometabolism in PD patients withmild cognitive impairment
(PD-MCI) with and without visual hallucinations. The table
showing the full data extraction is available at: https://drive.
google.com/file/d/0B0_JB3wzTvbpUHRSZ2NfSVZfVkE/
view?usp=sharing.
The critical outcomes were not available in any of the ex-
amined studies. The metabolic patterns associated with PD-
related cognitive impairment (i.e. MCI or dementia) as com-
pared with the patterns in patients with no PD-related cogni-
tive impairment were described by Yong et al. [22]. They
showed that in comparison with PD patients with no cognitive
impairment, patients with PD dementia (PDD) showed greater
metabolic deficits in the parietal and frontal regions but that
metabolic patterns in PDD patients and patients with Lewy
body dementia were broadly similar.
Two longitudinal studies did identify specific patterns of
hypometabolism in PD patients who developed cognitive de-
cline during follow-up compared with the patterns in PD pa-
tients who did not develop cognitive impairment. In the first
study, 6 of 23 patients with PD developed dementia during
follow-up. Patients with progression to PDD had decreased
metabolism in the visual association cortex, posterior cingu-
late cortex and caudate nucleus at baseline (at a time when no
major cognitive impairment was present). With progressive
impairment, the hypometabolism became more widespred
widely to the neocortical regions [23]. In the second study,
PD patients who declined had hypometabolism in the posteri-
or and temporal areas of the brain at baseline, in contrast to PD
patients with stable cognition over time [24]. However, a
quantitative assessment of discrimination accuracy was not
provided. Three further studies [25–27] analysed data from
the same sample of patients and showed decreased prefrontal
and parietal metabolism in PD-MCI patients relative to PD
patients with no cognitive impairment, as well as an increase
in brainstem/cerebellar metabolism.
The availability of formal evidence supporting the utility of
FDG PET for identifying PD-related neurodegeneration in
patients with PD at risk of cognitive impairment was therefore
‘lacking’. Nevertheless, the consensus-based recommenda-
tion was achieved on Delphi round IV, with five panellists
voting for the clinical use of FDG PET based on the presence
of cortical hypometabolism in PD patients prior to the onset of
cognitive decline (Fig. 2).
PICO question 13: Discriminate PSP from PD
Of 54 studies identified and screened by the assigned panellist
(F.N.), 38 were sent to the methodology team (see Fig. 1), and
of these 33 were excluded: 20 studies did not include PSP [28]
or PD patients [29–47], 5 studies did not directly and exclu-
sively compare PSP and idiopathic PD [38, 48–51] and the
remaining 7 studies [52–58] reported associations only. The
data extraction table is available at: https://drive.google.com/
file/d/0B0_JB3wzTvbpNnEwTmRzX3pmdlU/view?usp=
sharing). Critical outcomes were available in two of the
examined studies (see Table 2), which included 36 patients
Table 1 Availability of evidence and panellists’ decisions supporting the use of FDG PET in the diagnostic work-up of the main forms of parkinsonism
PICO question Relative availability
of evidence
Panellists’
recommendations
Main reasons for final decision
12 (PD-related decline) Very low/lacking Yes Sensitive to cortical involvement before
cognitive deficits appear
13 (PSP) Very low/lacking Yes Presence of typical hypometabolic patterns
15 (CBS) Fair Yes Presence of typical hypometabolism
Delphi decisions for the other PICO questions of the EANM/EAN initiative led to supporting FDG PET in all clinical scenarios [1] with the exception of
preclinical cases [9] and of amyotrophic lateral sclerosis and Huntington’s disease [10]
Fig. 2 A 67-year-old patient with de novo PD and subtle cognitive im-
pairment (amnestic MCI), MMSE score 29/30 and high educational level.
The FDG PET image shows bilateral posterior parieto-occipital
hypometabolism with sparing of the posterior cingulate cortex
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with PSP and 32 with idiopathic PD. In these studies FDG
PET was able to discriminate PSP from PD with sensitivities
of 52.9–75%, specificities of 80–100% and accuracies of 67.
6–83.9% [59, 60], and an AUC of 0.80 [60].
Additional outcomes were reported in three additional stud-
ies [61–63] using a two-step classification, consisting first of
discriminating idiopathic PD from atypical parkinsonism, and
then discriminating PSP from other atypical parkinsonism. In
these studies, FDG PET demonstrated good sensitivity in dis-
criminating idiopathic PD from atypical parkinsonism (range
83–86%) and a moderate sensitivity in diagnosing PSP and
discriminating it from CBD and MSA (range 73–88%).
Specificity and PPV were both greater than 90% in discriminat-
ing idiopathic PD from atypical parkinsonism (range 94%–97%
and 96%–98%, respectively) and in discriminating various sub-
types of atypical parkinsonism (range 90%–94% and 85%–
96%, respectively). The NPV for discriminating idiopathic PD
from atypical parkinsonism was moderate (range 76–83%).
The five studies had a moderate risk of bias regarding the
index test. In the studies byMudali et al. [59] and Srulijes et al.
[60], the level of blindness of the FDG PET reader to the
clinical diagnosis was unclear and in those by Teune et al.
[57] and again Srulijes et al. [60], the execution of the index
test was not described in sufficient detail to allow replication.
Further, there was low applicability of all studies due to all
studies having included a selected population and having used
a semiquantitative method of image analysis.
Taking into account the available evidence for the PICO
questions of the entire project, the level of evidence
supporting the clinical use of FDG PET for discriminating
PSP from idiopathic PD was considered as ‘lacking’.
However, the consensus recommendation to support the use
of FDG PETwas defined on Delphi round III and was based
on the presence of a typical metabolic pattern of
hypometabolism in PSPwhich predominantly affects the fron-
tal, thalamic, striatal and midbrain regions (Fig. 3).
PICO question 15: Identify the underlying
pathological process in patients with corticobasal
syndrome
Among the 41 studies identified by the assigned panellist
(F.N.), 32 were sent to the methodological team (see Fig. 1).
Two studies [38, 59] were excluded because they did not
include CBS patients. The table reporting the data extraction
is available at: https://drive.google.com/file/d/0B0_
JB3wzTvbpamRDZnNpV2VQSE0/view?usp=sharing).
Critical outcomes were available in two of the examined
studies (Table 3). Both studies [64, 65] used amyloid-PET as
the gold standard for clinical diagnosis, and tested the ability
of FDG PET to predict AD pathology in a total of 39 patients
with CBS. Sensitivity ranged from 91% to 95%, specificity
from 58% to 75%, and accuracy from 73% to 82%. Taswell
et al. [65] also reported a PPVof 68%, NPVof 97%, LR+ of 3.
90 and LR− of 0.06.
Both studies had a low risk of bias for all items, and mod-
erate applicability concerns. Because of the paucity of results,
accuracy of differential diagnosis between CBD and idiopath-
ic PD or other atypical parkinsonism, and prediction of years
of survival were added as additional outcomes. They were
extracted from 9 of the 28 remaining studies:
– Differential diagnosis between CBS and other atypical
parkinsonism was described in four studies [48, 50, 51,
61]. They showed moderate-to-good sensitivity (81–
91%) and very good specificity (91–100%).
– Differential diagnosis between CBD and PSP was
analysed in four studies [30, 32, 41, 54]. They showed
good AUC (0.92–0.97), moderate sensitivity (76–79%)
and heterogeneous specificity (69–92%).
– Predictability of survival: in the study by Hellwig et al.
[54], FDG PET alone was an independent predictor of
survival in patients with parkinsonism (age-adjusted haz-
ard ratio: 5.15 for PSP/CBS FDG PET diagnosis).
– Cordato et al. [66] reported similar hypometabolic pat-
terns in autopsy-confirmed CBD and PSP.
In all of these studies, the most frequent pattern of
hypometabolism associated with CBS included asymmetrical
hypometabolism of the parietal and frontal cortex, thalamus
and basal ganglia. The occipital cortex and cerebellum were
usually spared. Considering the entire project, the availability
of formal evidence supporting the clinical use of FDG PET in
Fig. 3 A 58-year-old patient with PSP and mild cognitive impairment
(non-amnesic multiple domainMCI; MMSE score 26/30). The FDG PET
image shows moderate hypometabolism of the bilateral frontal cortex,
including the medial frontal gyri, and hypometabolism of the caudate
nuclei mainly in the right hemisphere, and in the right thalamus
1540 Eur J Nucl Med Mol Imaging (2018) 45:1534–1545
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identifying the underlying neuropathology in CBS patients
was considered as ‘fair’. Consensus was achieved on Delphi
round I, with six panellists supporting the clinical use of FDG
PET based on the specific asymmetry of the pattern of
hypometabolism (Fig. 4).
Discussion
We assessed the evidence for the clinical utility of FDG
PET in diagnosing idiopathic PD and atypical parkinson-
ism associated with dementia. The evidence supporting the
clinical use of FDG PET for identifying PD-related neuro-
degeneration associated with impaired cognition and for
discriminating PSP from idiopathic PD was lacking.
Conversely, the evidence supporting the clinical use of
FDG PET for identifying the underlying neuropathology
in patients with CBS was fair. Despite the low quality of
evidence available from published studies, the Delphi pan-
el voted for recommending the clinical use of FDG PET in
the differential diagnosis of conditions characterized by
parkinsonism and dementia (PICO question 12).
The reasons given by panellists during the Delphi panel pro-
cess focused on both the clinical utility of the NPVof FDG PET,
and also on the PPVof typical patterns of hypometabolism. In
particularfor theidentificationofimpendingPD-relatedcognitive
decline, thepanellists recommended the clinical use ofFDGPET
because patients with PDD or PD-MCI have a typical pattern of
hypometabolismmainlyaffectingtheposteriorcorticalareas.The
prognosticvalueofFDGPETwasalsoconsidered tobeclinically
relevant in the identification of patients who may benefit from
early cholinesterase inhibitor treatment or other future symptom-
atic treatments.A recently published study [67] showed that
FDG PETwith statistical parametric mapping detected pat-
terns of hypometabolism that predicted the risk of a patient
with PD having progressed to dementia by 4 years with
85% sensitivity and 88% specificity. However, this study
was not available at the time of the literature search and
therefore was not considered in the Delphi process.
Atypical hypometabolism of mainly posterior cortical
areas on FDG PET could therefore be added to the list of
other helpful investigations which include reduced dopa-
mine transporter uptake in the caudate, CSF amyloid β
(Aβ1-42) to t-tau ratio and APOE ε4 status [3], and is a
risk factor for cognitive deterioration in idiopathic PD.
For PICO question 13, panellists based their decision to sup-
port the clinical use of FDG PET for discriminating PSP from
idiopathic PD on the presence of a typical metabolic pattern for
PSP, which is not present in PD. PSP is characterized by
hypometabolism in the medial frontal and anterior cingulate
cortices, and in the striatum andmidbrain. FDG PETmay there-
fore be useful in early stages of the disease, when the clinical
diagnosis is less certain. Perfusion SPECT, albeit less precise
because of poorer spatial resolution, also displays a consistent
pattern [68, 69]. The described abnormalities in PSP can be
difficult to detect in very early stages by visual analysis alone
and a semiautomated assessment, comparing the pattern in the
patient with the pattern in age-matched controls is recommend-
ed in addition to visual reading, consistent with recommenda-
tions of the present EANM-EAN initiative [70]. While a PSP-
related pattern has been repeatedly demonstrated [33, 62, 71],
data are still incomplete if different PSP phenotypes are consid-
ered, such as PSP-P or pure akinesia with gait freezing. These
may be characterized by less severe or incomplete patterns,
compared with typical and full-blown PSP. The panellists’ de-
cision was consistent with both the EANM procedural guide-
lines [72] and the more recent diagnostic criteria of the
Movement Disorder Society [5, 73], which support the use of
FDG PET for discriminating PD from atypical parkinsonian
syndromes.
Regarding CBS (PICO question 15), an asymmetrical corti-
cal hypometabolism is known to affect the hemisphere contra-
lateral to the side with akinetic-rigid parkinsonism and apraxia.
This hypometabolism is typically found in the motor and
premotor cortices, but may also involve the prefrontal or poste-
rior parietal and lateral temporal cortex, and the cingulate gyrus.
The heterogeneity of metabolic patterns found in CBS when no
autopsy diagnosis is available is most likely due to the variety of
different pathologies that can present as CBS. These include
CBD, PSP, AD and frontotemporal dementia, and amix of these
conditions. The future challenge is to differentiate the metabolic
Fig. 4 A 76-year-old patient with CBS and mild cognitive impairment
(non-amnestic, multiple domain MCI; MMSE score 28/30). The FDG
PET image shows severe hypometabolism in the whole right hemisphere,
including the basal ganglia and thalamus, with more severe
hypometabolism in the temporoparietal cortex. Dopamine transporter
SPECT imaging showed severely reduced uptake in the right basal gan-
glia, suggesting CBD
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patterns associated with different underlying pathologies and
will require either neuropathological confirmation of the diag-
nosis by autopsy or the use of additional imaging methods, for
example tau-PET and amyloid-PET as the gold standard.
Considering the large number of studies published, the fact
that the majority had severe limitations and did not allow the
generation of evidence that could confidently support the clin-
ical use of FDG PET in the three PICO scenarios was striking.
It is important that future studies seek to recruit sufficient
numbers of patients and have a robust clinical diagnosis and
follow-up and ideally include additional imaging or other bio-
markers to strengthen diagnostic certainty. Studies should
preferably include autopsy diagnosis as the gold standard.
Other important considerations are appropriate clinical com-
parisons, innovative statistical analysis and the use automatic
semiquantitative assessment in addition to visual assessment,
to help the nuclear medicine physician interpret findings and
to increase specificity and/or sensitivity. In the case of PD,
analysing FDG PET using a spatial covariance method could
identify characteristic patterns of metabolism in PD with and
without cognitive decline. This could be helpful in future re-
search not only to aid more accurate diagnosis but also to
evaluate the effect of new therapeutic interventions [74].
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